EGFR-mutated NSCLC: practice-changing results and other notable findings

被引：0
|
作者：
不详
机构：
来源：
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY | 2023年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S188 / S192
页数：5
相关论文
共 50 条
  • [41] NSCLC presents metabolic heterogeneity, and there is still some leeway for EGF stimuli in EGFR-mutated NSCLC
    Mendes, Cindy
    Lemos, Isabel
    Francisco, Ines
    Almodovar, Teresa
    Cunha, Fernando
    Albuquerque, Cristina
    Goncalves, Luis G.
    Serpa, Jacinta
    LUNG CANCER, 2023, 182
  • [42] Novel concept of EGFR-signal contribution to unique immunological status in EGFR-mutated NSCLC
    Sugiyama, Eri
    CANCER SCIENCE, 2022, 113 : 638 - 638
  • [43] Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC
    Kobayashi, Keigo
    Tan, Aaron C.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (04)
  • [44] Clinical advances in EGFR-TKI combination therapy for EGFR-mutated NSCLC: a narrative review
    Zhang, Qianru
    Wang, Ruo
    Xu, Lu
    TRANSLATIONAL CANCER RESEARCH, 2023, 12 (12) : 3764 - 3778
  • [45] EGFR-Mutated PDX in NSCLC: Molecular Fidelity and Correlation of PDX and Patient Response to EGFR Inhibition
    Riess, Jonathan W.
    Gandara, David R.
    Tsai, Rebekah A.
    Cheng, Mingshan
    Holland, Will S.
    Crawford, Kaitlin D.
    Yang, Hongyuan
    Li, Tianhong
    Lara, Primo, Jr.
    Kelly, Karen
    Airhart, Susan
    Graber, Joel
    Bult, Carol
    Keck, James G.
    Mack, PhilipC.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S311 - S311
  • [46] Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
    Mei-Mei Zheng
    Yang-Si Li
    Hai-Yan Tu
    Hao Sun
    Kai Yin
    Ben-Yuan Jiang
    Jin-Ji Yang
    Xu-Chao Zhang
    Qing Zhou
    Chong-Rui Xu
    Zhen Wang
    Hua-Jun Chen
    De-Xiang Zhou
    Yi-Long Wu
    BMC Medicine, 20
  • [47] Treatment Strategies and Survival Outcomes of Patients with EGFR-mutated NSCLC and leptomeningeal metastasis
    Fan, Y.
    Wu, H.
    Chen, K.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S652 - S652
  • [48] Safety and tolerability of lazertinib and in combination with amivantamab in advanced EGFR-mutated Japanese NSCLC
    Goto, Koichi
    Hida, Toyoaki
    Funami, Nobuyuki
    Iwasawa, Ryota
    Mita, Sachiko
    Yamashita, Aimi
    Imanaka, Keiichiro
    Kitani, Sumiko
    Ohe, Yuichiro
    ANNALS OF ONCOLOGY, 2021, 32 : S317 - S317
  • [49] Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB Study
    Riess, Jonathan W.
    Lara, Matthew S.
    de Rodas, Miguel Lopez
    Luxardi, Guillaume
    Herbert, Samantha
    Shimoda, Michiko
    Kelly, Karen
    Meerlev, Alexander
    Moore, Elizabeth
    Beckett, Laurel
    Monjazeb, Arta
    Schalper, Kurt
    Maverakis, Emanual
    Gandara, David R.
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (10):
  • [50] Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC Reply
    Cho, Byoung C.
    Sethi, Seema
    Spira, Alexander I.
    NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (06): : 620 - 621
12345